Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

76.25 -0.59 (-0.77%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Merck & Co Unusual Options Activity
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Political Tariff
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck & Co. Inc. (NYSE:MRK): A Potential Undervalued Opportunity
Merck & Co. Inc. (NYSE:MRK): A Potential Undervalued Opportunity 
Via Chartmill
Should Investors Buy Merck Stock After These Huge Risks?
Via The Motley Fool
Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
How To Put $100 In Your Retirement Fund Each Month With Merck Stock
Via Benzinga
Topics Retirement
Exposures Pension
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
From Merck & Co., Inc.
Via Business Wire
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth. 
Via Benzinga
Despite its impressive fundamentals,MERCK & CO. INC. (NYSE:MRK) remains undervalued.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
Exposures Political Tariff
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics. 
Via Benzinga
Topics World Trade
Exposures Tariff
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials. 
Via Benzinga
Exposures Product Safety
Market Monitor April 25 ( Texas Instruments, Nvidia & Amazon UP, IBM, PepsiCo & Comcast DOWN)
Wall Street Rallies Again: Tech Leads the Charge, Alphabet Shines After-Hours 
Via Chartmill
Merck (MRK) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings World Trade
Exposures Financial Tariff
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE... 
Via Stocktwits
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million
Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure. 
Via Benzinga
Topics Earnings
Exposures Financial
Merck & Co. Reports Better Than Expected Results For First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments. 
Via Talk Markets
Topics Stocks / Equities
Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story
US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline. 
Via Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens
Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million. 
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
Exposures Artificial Intelligence Financial Intellectual Property
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?
This is the third quarter of accelerating sales declines amid slow demand in China for Gardasil vaccines. 
Via Investor's Business Daily
Topics Earnings Government Stocks
Exposures Financial Political US Equities
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.